非洲HIV晚期就诊者的表型、风险及REALITY试验中的风险分层
REALITY试验纳入乌干达、津巴布韦、马拉维和肯尼亚CD4<100细胞/µL的ART初治成人和≥5岁儿童共1711例,48周内203例(12%)死亡。基于基线临床和实验室特征识别出五种晚期就诊表型,其中第1组死亡率最高(25%),第2组和第3组死亡率分别为11%和10%。
要点
- CD4<100细胞/µL启动ART者48周死亡率12%,第1组表型死亡率最高达25%。
- 高龄、低CD4、低白蛋白、低血红蛋白、低握力及WHO 3/4期体重下降等独立预测死亡。
- 接受增强抗菌预防独立降低死亡率(P=.02)。
核心结论
- 临床和实验室特征可识别ART启动后死亡率最高的患者群体。
- 筛查工具可识别低CD4计数患者,以优先安排当日启动ART、增强预防和强化随访。
研究设计与样本
- REALITY试验为在乌干达、津巴布韦、马拉维和肯尼亚开展的试验,纳入CD4计数<100细胞/µL的ART初治成人和≥5岁儿童。
- 共纳入1711例参与者,采用Cox回归(后退法,退出P>.1)识别48周内死亡的基线预测因素。
主要发现
- 1711例中203例(12%)死亡。
- 死亡率独立升高与高龄、较低CD4计数、较低白蛋白、较低血红蛋白、较低握力、存在WHO 3/4期体重下降、发热或呕吐、以及基线活动或自我照顾问题相关(均P<.04)。
- 接受增强抗菌预防独立降低死亡率(P=.02)。
- 第1组(n=355)死亡率最高(25%;中位CD4计数28细胞/µL),伴有高症状负担、体重下降、活动差、低白蛋白和低血红蛋白。
- 第2组(n=394;死亡率11%;CD4计数43细胞/µL)也有体重下降,白细胞、血小板和中性粒细胞计数高提示潜在炎症/感染。
临床怎么用
- 作者认为,筛查工具可识别低CD4计数患者,以优先安排当日启动ART、增强预防和强化随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severely immunocompromised human immunodeficiency virus (HIV)-infected individuals have high mortality shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and "late presenter" phenotypes. METHODS: The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years of age with CD4 counts <100 cells/µL initiating ART in Uganda, Zimbabwe, Malawi, and Kenya. Baseline predictors of mortality through 48 weeks were identified using Cox regression with backwards elimination (exit P > .1). RESULTS: Among 1711 included participants, 203 (12%) died. Mortality was independently higher with older age; lower CD4 count, albumin, hemoglobin, and grip strength; presence of World Health Organization stage 3/4 weight loss, fever, or vomiting; and problems with mobility or self-care at baseline (all P < .04). Receiving enhanced antimicrobial prophylaxis independently reduced mortality (P = .02). Of five late-presenter phenotypes, Group 1 (n = 355) had highest mortality (25%; median CD4 count, 28 cells/µL), with high symptom burden, weight loss, poor mobility, and low albumin and hemoglobin. Group 2 (n = 394; 11% mortality; 43 cells/µL) also had weight loss, with high white cell, platelet, and neutrophil counts suggesting underlying inflammation/infection. Group 3 (n = 218; 10% mortality) had low CD4 counts (27 cells/µL), but low symptom burden and maintained fat mass. The remaining groups had 4%-6% mortality. CONCLUSIONS: Clinical and laboratory features identified groups with highest mortality following ART initiation. A screening tool could identify patients with low CD4 counts for prioritizing same-day ART initiation, enhanced prophylaxis, and intensive follow-up. CLINICAL TRIALS REGISTRATION: ISRCTN43622374.
引用
- Siika A, McCabe L, Bwakura-Dangarembizi M, et al. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clin Infect Dis. 2018. PMID: 29514235. doi:10.1093/cid/cix1142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。